The nation of Zimbabwe has turned down a substantial US healthcare agreement valued at 367 million US dollars (£272m) spanning five years over Washington's insistence on confidential biological samples.
The decision came to light following a internal memorandum dated December was leaked, revealing that President Emmerson Mnangagwa deemed the agreement was "skewed".
A government spokesperson later stated that the United States was seeking biological samples for research and commercial purposes while was unwilling to guarantee the resulting advantages from any future treatments.
"We will now turn to the challenging and unfortunate task of winding down our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for further dialogue to secure a agreement acceptable to all parties so the country's vital HIV treatment initiative can be sustained.
Broader Background
This rejection follows a comparable situation in Kenya, where a high court blocked a similar deal with the US following concerns were raised about the safety of Kenyans' medical information.
Since resuming the presidency recently, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump stated its expenditure was "wasteful" and his government was pursuing direct bilateral agreements to enhance openness and responsibility.
As per statements, 16 nations in Africa have to date agreed to these new agreements, constituting over $18.3bn of fresh investment.
Specifics of the Declined Deal
This assistance for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this partnership could have provided extraordinary benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently on antiretroviral therapy via American-funded initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"Our nation was requested to provide its genetic material and health information for a long time, without any corresponding assurance of benefiting from any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," his statement read.
"Effectively, our nation would supply the basic resources for medical research without any assurance that the end products would be accessible to our people should a future health crisis arise."
Sovereignty and International Frameworks
He also said that the American exit from the global health body and its push of bilateral deals were disrupting structures previously established through the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme designed to deal with future global health emergencies.
"This framework is designed to guarantee that when a nation provides its samples, the benefits – including vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the funds to develop them."
These objections over the US deal "are not meant as anti-American sentiment," he added.
"We encourage continued discussions with our US partners on how subsequent collaboration could be structured in a way that honours the sovereignty and dignity of both nations."
Medical Community Response
Medical experts expressed it understood the government's concerns, but recommended that negotiations need to persist given that much of the country's Aids initiatives were funded by foreign aid.
"If specific concerns exist, including those relating to data governance or implementation frameworks, these can frequently be addressed through technical clarification and mutually agreed protections," it said.
The halted deal underscores the complex debate between accepting vital foreign assistance and safeguarding a country's data in an ever more data-driven world.